תבנית:תרופה/נובונורם 2 מ"ג - Novonorm 2 mg
ש××× ×× !
×ת×ר××: 30/07/2025 ×תק××× ××××¢× ×× ×©×××ק ×תר××¤× ××פסק ×צ××ת×ת.
×ת×ר××: 30/07/2025 ×תק××× ××××¢× ×× ×©×××ק ×תר××¤× ××פסק ×צ××ת×ת.
×ק×ר: ××©×¨× ××ר×××ת - ××××¢×ת ×¢× ×פסקת ש×××ק תר×פ×ת
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |
|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | A10BX Other blood glucose lowering drugs, excluding insulins |
| ×ר××× ×¤×¢×× (ATC5) | Â
|
| צ×רת ××ª× | פ××× - PER OS |
| צ×רת ××× ×× | ×××××, TABLETS ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× |
| ×ת×××× | Repaglinide is indicated in adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in adults with type 2 diabetes mellitus who are not satisfactorily controlled on metformin alone.Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.
|
| ת×× ×ת:× ×ª×× × ×¡×/תר×פ×/× ×××× ××¨× 2 ×"× - Novonorm 2 mg | |
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  |
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| × ×××× ××¨× 2 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | - |
|---|---|
| ××××¢ ×רשת | - |
| ×©× ××¦×¨× | NOVO NORDISK A/S, DENMARK |
| ×©× ××¢× ×ר×ש×× | NOVO NORDISK LTD, ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 07/2011. ר×ש××× ×ת×ר××: 06/2014 |
| ת×ר×× ×¢×××× ××ר×× | 30/07/2025 |
××£ ×× × ×צר ×¢× ××× ××× ×××××ר ת×× ×ת ×¢× ×¤×¨×× ×תר×פ×.
- ××£ ×תר×פ×: × ×××× ××¨× 2 ×"× - Novonorm 2 mg
- ××ר××¡× ××× ×ת ×©× ×¤×¨×× ×תר×פ×: × ××ª× ×ער×× ×ת ××£ ×תר××¤× ××¢××. ×××××× ×××××¤× ×ת:
{{תר×פ×/× ×××× ××¨× 2 ×"× - Novonorm 2 mg}}
×:
{{תר×פ×/× ×××× ××¨× 2 ×"× - Novonorm 2 mg
| ×©× ×פר××ר=×¢×¨× ××ש (××רס ×ת ××¢×¨× ×©×××× ××××ר)
}}
השינוי האחרון נעשה בֹ־17 בספטמבר 2025 ב־10:16